Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 989 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diseases of the Musculoskeletal System and Connective Tissue Clear all

Conditions: Psoriatic Arthritis
Interventions: adalimumab; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: Rheumatoid Arthritis (RA)
Interventions: ABBV-154, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 101
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more

Conditions: Rheumatoid Arthritis, Osteoarthritis
Interventions: Cura-100; Drug
Lead sponsor: Cura Biotech LLC; Industry
Eligibility: 20 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Sunnyvale, California

Conditions: Tinea Pedis, Athlete's Foot, Foot Fungus, Ringworm
Interventions: Sertaconazole nitrate cream 2%; Drug
Lead sponsor: Jamaica Hospital Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Jamaica, New York

Conditions: Psoriatic Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 17
States / cities: Phoenix, Arizona • Colorado Springs, Colorado • Bridgeport, Connecticut + 14 more

Conditions: Stress, Job, PTSD, Hypervigilance, Hyperthyroidism, Migraine, Migraine With Aura, Immunodeficiency, Sickle Cell Trait, Sickle Cell Disease, Anemia, Sickle Cell, Anemia, Fatigue, Anxiety, Depression, Flat Feet, Lordosis, TBI (Traumatic Brain Injury), Rheumatoid Arthritis, Arthritis, Masturbation, Priapism, Erectile Dysfunction, Flight Reaction, Hypertension, Sexual Arousal Disorder, Hemorrhoids, Fibroid
Interventions: Holistic Medicine (HM); Behavioral
Lead sponsor: Goddess Zena I. Jones; Other
Eligibility: 22 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Anchorage, Alaska

Conditions: Arthritis, Juvenile Rheumatoid, Uveitis
Interventions: Chicken type II collagen; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: US-ANSWER-2 decision aid, Control group (Online medication guide); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis
Interventions: Tanezumab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: La Mesa, California

Conditions: Nervous System Malformations, Arthropathy, Neurogenic, Urticaria, Papilledema
Interventions: anakinra; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Secukinumab (AIN457), Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 39
States / cities: Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 34 more

Conditions: Arthritis
Interventions: Blood Draws for Serum Titers; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 9 Years to 26 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 4
States / cities: Chicago, Illinois • Cleveland, Ohio

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol; Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 857 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 19
States / cities: Huntsville, Alabama • San Diego, California • Danbury, Connecticut + 15 more

Conditions: Rheumatoid Arthritis
Interventions: Tetanus + pnemococcal vaccines alone, Abatacept + Vaccines; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 3
States / cities: Lenexa, Kansas • Baltimore, Maryland • Austin, Texas

Conditions: Early Rheumatoid Arthritis
Interventions: adalimumab, methotrexate; Biological · Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 30
States / cities: Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 26 more

Conditions: Systemic Lupus Erythematosus
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1993
U.S. locations: 3
States / cities: Birmingham, Alabama • Galveston, Texas • Houston, Texas

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 140,706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Interventions: FT839; Biological
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2040
U.S. locations: 1
States / cities: Fullerton, California

Conditions: Rheumatoid Arthritis
Interventions: Tregalizumab, Placebo; Drug
Lead sponsor: Biotest; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: Paradise Valley, Arizona • Springfield, Illinois • Lincoln, Nebraska + 5 more

Conditions: Osteogenesis Imperfecta
Interventions: AGA2115, Placebo; Drug
Lead sponsor: Angitia Incorporated Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lake Forest, California

Conditions: Arthritis, Rheumatoid
Interventions: BMS-986528; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 11
States / cities: La Jolla, California • Loma Linda, California • Palo Alto, California + 7 more

Conditions: Rheumatoid Arthritis
Interventions: Rituximab, Methotrexate, Methylprednisolone, Folic Acid; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 21 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 42
States / cities: Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 36 more

Conditions: Rheumatoid Arthritis
Interventions: Filgotinib, Placebo to match filgotinib; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 2,731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 72
States / cities: Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more

Conditions: TGCT
Interventions: Emactuzumab, Placebo; Drug
Lead sponsor: SynOx Therapeutics Limited; Industry
Eligibility: 12 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: Beverly Hills, California • Los Angeles, California • Columbus, Ohio + 2 more

Search by objective public record fields.

Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

A Study Evaluating the Safety and Efficacy of Cura-100 in Subjects With Rheumatoid Arthritis and Osteoarthritis

Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

The Sequestration of Holistic Stress Management Techniques for Adults

The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis

Supporting Patient Care With Electronic Resources in the United States

Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis

Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis

A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers

Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)

Study of the Predictors of the Course and Early Outcome of Patients With Systemic Lupus Erythematosus: Nature Versus Nurture

A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register

FT839 in Autoimmune Diseases

Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)